📞 +1 628 258 0071(US)  📞 +44 2035 002 764(UK)
Gene Therapy Market Research Report - Forecast till 2027

Gene Therapy Market Research Report: By Product (Kymriah, Luxturna, Yescarta, Zolgensma, Strimvelis, Zynteglo), Indication (Oncology, Genetic Diseases) and End-User (Hospitals & Clinics, Specialty Treatment Centers) - Forecast to 2027

ID: MRFR/HC/6927-HCR | February 2021 | Region: Global | 111 pages

Gene Therapy Market Speak to Analyst Request a Free Sample

Gene Therapy Market Overview

The Gene Therapy Market size was valued USD of 524 million in 2018 and expected to grow at CAGR of 23.30% during 2021 to 2027. 

Gene Therapy is a strategy where a piece of DNA is joined into the cell through a vector. The central participants are putting resources into the assembling of cell and Gene Therapy medicines because of its objective explicitness. Gene Therapy is a principal of two sorts, physical quality treatment and Gene Therapy treatment, contingent upon the kind of cells its objectives. 

The development of the Gene Therapy Market Size depends on factors like vigorous item pipeline, expanding venture by vital participants, and high predominance of target illnesses and interest for creative medicine. Notwithstanding, the significant expense of item improvement and tough administrative strategies is relied upon to check the Gene Therapy Market Value development. The Gene Therapy Industry is right now overwhelmed by a few market players. These market players are playing an effective role in expanding the growth of the market to a great extent. The central members are engaged with item dispatches and key joint efforts to reinforce their market positions.  

The best part of Gene Therapy is that it involves supplanting, quelling, and fixing broken qualities that cause sickness. The point of this promising treatment is in restoring the ordinary capacity. This treatment assists with treating diverse hereditary sicknesses like acquired issues, in particular malignancy and viral contaminations, and some particular hereditary infections, specifically strong dystrophy, and cystic fibrosis. There are various elements that are driving the Gene Therapy Market Growth development. It includes expanding assets for quality treatment research, accessibility of positive repayments, expanding instances of malignancy and other objective illnesses, and key coordinated efforts and item dispatches made by central participants for remaining ahead in the opposition. 

Additionally, rising instances of target infections, enormous ventures made by top market players, and a strong item pipeline are likewise adding quality treatment market growth. These growth factors must be properly taken care of in order to enhance the market growth. In the Gene Therapy Industry, you may find different drivers, opportunities, challenges, restraints, and growth factors on the market condition is mostly dependent. 

Covid-19 Analysis

The utilization of hereditary Gene was a focal apparatus in understanding the impact of a few sicknesses, even the COVID-19 contamination. The component of exactness in Gene Therapy is assessed to set out more open doors for the market as it tends to be sent adequately to treat sicknesses that don't have any therapy yet. Gene Therapy is accessible to convey a viable therapy decision for patients that have progressed protection from chemotherapies across various malignancy signs. The spread of covid-19 has impacted the Gene Therapy market to a great extent. There is a high demand for Gene Therapy due to the covid-19 situation, which ultimately enhances the market's growth. 

Market Dynamics


The market for Gene Therapy is assessed to be reinforced by a vigorous item pipeline. The developing financing by key players is anticipated to make positive scenery for improvement in the coming years. Likewise, the raised event of target infections and creative medicine necessities is expected to prod the Gene Therapy Industry for the forecasted market.


The different components driving the Gene Therapy market incorporate the rising occurrence of malignancy and different sicknesses, developing a quality treatment pipeline and expanding subsidizing for the Gene Therapy research. But the significant expense related to Gene Therapy and not many repayment options is considered as a challenging factor in the Gene Therapy market. Hence this challenge must be effectively dealt with in order to enhance the growth of the Gene Therapy Industry. 


An increment in subsidizing and venture for progressions in quality treatments are required to give rewarding development freedoms to the key players. It is considered an effective opportunity that is driving the growth of the Gene Therapy market. Moreover, organizations are occupied with key unions to support their contributions in the space, which is expected to heighten the market rivalry during the estimated time frame.


The Gene Therapy market is evaluated to be limited because of the raised expense of item improvement for a few treatments. Besides, the thorough administrative approaches are anticipated to additionally decrease the development of the Gene Therapy Industry in the estimated time frame.

Cumulative growth Analysis

The extending field of cutting-edge treatments and Gene conveyance advances has made an undeniably aggressive powerful where a considerable number of market players are occupied with the commercialization of their Gene Therapy items. Treatment designers put resources into the joint effort and secure bargains as a suitable system to improve in-house aptitude and fortify item pipelines. These elements are required to help the Gene Therapy market development. Besides the high costs of presently accessible treatments, the Gene Therapy market growth is boosted. But the lack of Gene Therapy availability can bring down the Gene Therapy Industry growth because of the absence of monetary suitability of the items.

Segment Overview

  • By Product

Based on product, the Gene Therapy market is portioned into Strimvelis, Kymriah, Luxturna, Imlygic, Yescarta, Zolgensma, Zynteglo, and much more. Kymriah and Luxturna are the principal endorsed Gene Therapy and, in this manner, hold a significant offer in the Gene Therapy Industry. Kymriah is utilized to treat intense lymphoblastic lymphoma, while Luxturna is utilized to treat retinal dystrophy. Imlygic is the first oncolytic viral treatment. 

  • By Indication

Based on indications, the Gene Therapy Industry is divided into oncology, hereditary illnesses, and much more. The hereditary infections section holds the biggest offer in the Gene Therapy market. At the same time, the oncology fragment is required to develop at the most elevated rate over the estimated time frame. 

  • By End-user

Based on end-use, the worldwide quality treatment market is portioned into forte treatment habitats, clinics and facilities, and much more. Medical clinics and facilities contain the biggest portion of the Gene Therapy market.

Regional Analysis 

The Gene Therapy market has been partitioned, based on region, into the Asia-Pacific, Americas, Europe, and the Middle East, and Africa. The Americas must be the biggest market attributable to the expanding pervasiveness of quality treatment and rising per capita medical care consumption. The Gene Therapy Industry in the Americas has additionally been fanned into North America and Latin America, with the North American market separated into the US and Canada. The European quality treatment market has been sorted as Western Europe and Eastern Europe. The Western European market has also been delegated to Germany, France, the UK, Italy, Spain, and Western Europe. The Gene Therapy market in Asia-Pacific has been portioned into Japan, China, India, South Korea, Australia, and the remainder of Asia-Pacific. Because of the expanding number of patients and bringing issues to light about the treatment strategies, the market in Asia-Pacific is relied upon to be the quickest developing. The Gene Therapy Industry in the Middle East and Africa has been separated into the Middle East and Africa.

Major Market Players

The key players of the Gene Therapy market

  • Amgen, Inc. (US)

  • Spark Therapeutics, Inc. (US)

  • Bristol-Myers Squibb Company (US)

  • Novartis AG (Switzerland)

  • Gilead Sciences, Inc. (US)

  • Celgene Corporation (US)

  • Thermo Fisher Scientific Inc. (US)

  • CEVEC (Germany)

  • uniQure N.V. (Netherlands)

  • Orchard Therapeutics plc (UK)

  • Lonza (Switzerland)

Recent Developments

  • In 2019, the oncology portion represented more than 40% of the worldwide cell and Gene Therapy Industry. Oncology has been one of the objectives of extraordinary exploration for the quality treatment strategies and approaches.

Report Overview

  • Market overview highlights the global recognition of Gene Therapy Market Analysis overview

  • Analysis based upon COVID 19

  • Explanation upon the Market Dynamics

  • Value chain analysis for the market Share Report.

  • Market segmentation overview

  • The regional analysis of Market Trends overview

  • Competitive landscape analysis

  • Recent Developments of Market Forecast

The report highlights the Gene Therapy Market Growth development includes its revenue hike's growth potential by the end of the forecast years in 2028.

Report Scope:
Report Attribute/Metric Details
  Market Size

  • 2018: USD 524 Million
  • 2027: Significant Value
  •   CAGR   23.30% (2021-2027)
      Base Year   2019
      Forecast Period   2020-2027
      Historical Data   2018
      Forecast Units   Value (USD Million)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Product, Indication, End-User
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Amgen, Inc. (US), Novartis AG (Switzerland), Spark Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), uniQure N.V. (Netherlands), Orchard Therapeutics plc (UK), Celgene Corporation (US), Bristol-Myers Squibb Company (US), Thermo Fisher Scientific Inc. (US), CEVEC (Germany), Lonza (Switzerland)
      Key Market Opportunities   New product launches and R&D Amongst major key Players
      Key Market Drivers

  • Robust product pipeline
  • Increasing investment by key players
  • High prevalence of target diseases and demand for innovative medication

  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    Based on product, Gene therapy industry divided into kymriah, luxturna, yescarta, zolgensma, strimvelis, zynteglo, imlygic, and others. Kymriah: Novartis AG reported an annual sale of USD 28 million in 2018. Zynteglo: The drug indicated for transfusion-dependent β thalassaemia (TDT), is the second most expensive drug valued at an approximate value of USD 1.8 million. Yescarta: The drug was approved by the US Food and Drug Administration (FDA), in 2018, for the treatment of B-cell lymphoma.

    The key players are investing in the manufacturing of cell and gene therapy treatments due to its target specificity. In the regional market Asia-Pacific is expected to be the fastest-growing market. On the basis of Indication The oncology segment is expected to hold the largest market share and to be the fastest-growing segment due to high prevalence of cancer and robust pipeline for cancer gene therapy.

    The gene therapy market had reached a valuation of USD 524 MN in 2018.

    The gene therapy market is projected to grow at approximately 40.7% CAGR during forecast period (2019-2025).

    Rising technological advances and favorable government initiatives.

    North America holds the largest share in the gene therapy market, followed by Europe and the Asia Pacific, respectively.

    Novartis AG (Switzerland), Amgen, Inc. (US), Spark Therapeutics, Inc. (US), uniQure N.V. (Netherlands), Gilead Sciences, Inc. (US), Orchard Therapeutics plc (UK), Bristol-Myers Squibb Company (US), Celgene Corporation (US), Thermo Fisher Scientific Inc. (US), Lonza (Switzerland), and CEVEC (Germany), are some of the major players operating in the gene therapy market.